Cosán and Genomind Partner to Help Prevent Prescription Drug Adverse Events in Older Adults

Cosán and Genomind Partner to Help Prevent Prescription Drug Adverse Events in Older Adults

Genomind’s analytical capabilities will provide Cosán with risk stratification information, allowing Cosán clinicians to target those most likely to benefit from drug reviews and pharmacogenetic (PGx) testing.

Cosán, a provider of technology-driven preventative care services for older adults and the physicians who assist them, and Genomind, a leading precision healthcare company, have partnered to fill an existing gap in management aging adult care by providing Cosán’s physician network with Genomind’s integrated precision medication management platform. The platform will provide insights that will help Cosán achieve the best outcomes for its patient population, prevent adverse drug events, and reduce the avoidable costs of drug mismanagement.

With more than 40% of US adults age 65 and older taking five or more prescription medications, aging populations are at high risk for adverse drug events. Through this partnership, Genomind’s analytical capabilities will provide Cosán with risk stratification insights, allowing Cosán clinicians to target those most likely to benefit from drug reviews and pharmacogenetic (PGx) testing, also known as the name of genetic drug testing. Genomind’s PGx test adds a layer of precision medicine that leverages genetics to help providers select appropriate medications and dosage. Equipped with advanced pharmacogenetic screening, clinical concierge services and access to expert pharmacists, Cosán’s care teams can then integrate individualized information into each patient’s chronic care management plan so that medications be administered safely.

“This partnership brings a new level of pharmaceutical and genetic expertise to thousands of providers and the patients they serve, marking another milestone in delivering effective preventive care management services,” said David Hunt, Founder and President of Cosan. “These unique drug analysis and genetic testing capabilities provide Cosán’s network of physicians and care coordinators with another tool designed to help eliminate preventable drug risks and improve the overall quality of care for patients. vulnerable people receiving home care.

According to the CDC, adverse drug events cause about 1.3 million emergency room visits each year, and older people are nearly seven times more likely to end up hospitalized after such events than younger people. Many of these adverse events are caused by just a few drugs. This new platform will help physicians develop personalized treatment approaches for patients based on their individual genetic makeup and is designed to improve patient and physician satisfaction and reduce medical expenses. With recent Medicare expansions to cover PGx testing under certain circumstances, this population is uniquely suited to benefit significantly from this platform.

“The prevalence and cost of medication mismanagement is unacceptable, costing thousands of lives and billions of dollars a year. We are excited to join Cosán in helping to improve care management for older adults, who are at high risk for these adverse drug events,” said Cynthia Kilroy, co-CEO of Genomind.

The Cosán/Genomind platform is currently in the pilot testing phase and is expected to be widely implemented this year.

About the Cosán Group

The Cosán Group, established in 2015, is an industry-leading healthcare organization creating new pathways to modern aging with technology-driven preventative care services, offering home concierge services for old people. Early market exposure in providing technology and services to support Chronic Care Management (CCM) program and Behavioral Health Integration (BHI) programs with Remote Patient Monitoring (RPM) has driven Cosán to provide a practical, patient-centered approach to telemonitoring. coordination of care. Visit our website: http://www.cosangroup.com

Media Contacts

Clinical Information: Desiree Martin – Vice President – Clinical Operations

[email protected]

Business Inquiries: Michael Knipper – Vice President, Sales and Strategic Partnerships

[email protected]

Press: Garth Cabral – Director of Marketing and Brand Management

[email protected]

About Genomind

Genomind is a leading precision health company focused on optimizing the treatment experience for individuals and healthcare providers through actionable genetic information and innovative health technology. Genomind’s platform integrates precision health technology and pharmacogenetic testing at the individual and population level beyond mental health. Built on the foundation of compassionate care and clinical expertise, Genomind enables a more focused and personalized approach to medication management and supports providers in a new standard of care.

Learn more at http://www.genomind.com.

Media Contacts

Clinical inquiries: David Krause, MD – [email protected]

Business Inquiries: Cynthia Kilroy – [email protected]

Share the article on social networks or by e-mail:

Comments are closed.